Skip to main content

What the FDA labels say about taking them together

Ensitrelvir and finerenone

Ensitrelvir's FDA label of June 3, 2026 names finerenone in its drug interactions section; the finerenone label PlainMeds reads does not name ensitrelvir. The ensitrelvir label: “Co-administration is contraindicated due to potential for serious adverse reactions, including hyperkalemia, hypotension, and hyponatremia.”

Check it at the source: the ensitrelvir FDA label on DailyMed (effective June 3, 2026, Shionogi Inc.); the finerenone FDA label on DailyMed (effective August 28, 2025, Bayer HealthCare Pharmaceuticals Inc.).

What does the ensitrelvir label say about finerenone?

Ensitrelvir label, drug interactions

Drug Class: Mineralocorticoid receptor antagonists; Drug (s) within Class: finerenone; Effect on Drug Concentration: ↑ finerenone; Clinical Comment: Co-administration is contraindicated due to potential for serious adverse reactions, including hyperkalemia, hypotension, and hyponatremia.

Source: FDA drug label (XOCOVA), Shionogi Inc., effective June 3, 2026 (SPL set 526acf60-abc3-2cc2-e063-6294a90affa6), via openFDA; the full label on DailyMed

What does the finerenone label say about ensitrelvir?

Finerenone's label (effective August 28, 2025) does not name ensitrelvir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Kerendia), Bayer HealthCare Pharmaceuticals Inc., effective August 28, 2025 (SPL set fc726765-5d5a-4d6e-b037-b847bda9fb7c), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Ensitrelvir generic labelers
0Finerenone generic labelers
EnsitrelvirFinerenone
Labeled forCOVID-19Chronic kidney disease
Boxed warningNoNo
Pharmacy cost (NADAC)n/a$22.86 per tablet 10 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?